Trump’s “Buy American” Executive Order Could Raise Drug Prices
Tensions escalate with pharma as President Trump signs an executive order (EO) today directing the federal government to buy certain [...]
What is the Global Access Impact of COVID-19? DRG and Context Matters Weighs In
Mike Ward, Global Head of Thought Leadership at Decision Resources Group talks with Steve Edgar of DRG Global Market Access [...]
Aetion analyzes RWE impact in 4 recent FDA decisions in infectious disease
Senior Directors from Aetion (Purpura and Harvey) analyzed four approvals for products intended to treat or prevent infectious diseases from [...]
Trump v. Pharma: a “Kinda Sorta” War
Politico summarizes Trump's "kinda sorta" war with pharma, kicked off last week with presidential tweets about "nasty" drug ads that [...]
Not interested: Pharma execs refuse White House meeting over drug pricing executive orders
Trump's recent executive orders linking drug prices in Medicare to lower prices abroad caused a significant rift with the pharma [...]
Viewpoint in JAMA: Integrating Personalized Medicine with Population Health Management: The Path Forward
In this viewpoint article published in the Journal of the American Medical Association, the authors posit that genome-wide DNA sequencing [...]
Dread Expressed by Public Health Experts on Hurried FDA Signoff on COVID-19 Vaccine
Eighty-nine sites are enrolling patients in the landmark Phase 3 trial for Moderna Therapeutics vaccine kicked off on Monday, July [...]
New Platform for Affordable Genomic Cancer Profiling Launched
A next-generation sequencing reference laboratory will use artificial intelligence (AI) to advance precision medicine to determine genomic signatures, first for [...]
IFAPP, MAPS Course Offers Certificate in Medicine Development
An online course hosted by IFAPP Academy in partnership with the Medical Affairs Professional Society (MAPS) aims to give medical [...]
Aetna Launching 2 New Plan Benefit Designs
Aetna announced plans to launch two new plan benefit designs aimed at addressing growing concerns by employers about high-deductible plans, [...]
NPC: CMS Proposed Rule Hinders Value-Based Arrangements
In a letter to the Centers for Medicare and Medicaid Services, the National Pharmaceutical Council (NPC) outlines some key issues [...]
Reminder: ICER Webinar on Cost-Recovery Pricing for COVID-19 Drugs is Tomorrow
The first installment of the Institute for Clinical and Economic Review's (ICER) three-part webinar series on drug pricing models for [...]
Webinar to Highlight Challenges of Value Assessment Amid Pandemic
An upcoming webinar sponsored by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Innovation and Value Initiative [...]
Datta: CMS Proposal a ‘Grab-bag of Issues’
Sidley Austin LLP's Meena Datta told HealthLeaders that the Centers for Medicare and Medicaid Services' (CMS) latest proposal is a [...]
DRG Offers COVID-19 Resources on Website
DRG has compiled a suite of resources to support life sciences companies amid the COVID-19 pandemic. "We've assembled resources to [...]
Eversana Acquires HVH Precision Analytics to Beef Up Data, Analytics Capabilities
Eversana has acquired HVH Precision Analytics from Havas Health & You in a bid to bolster its data analytics capabilities, [...]
Bach Outlines ‘Gaping’ Loophole in Medicaid Proposal
A Centers for Medicare and Medicaid Services proposal includes a "gaping" loophole through which drugmakers could avoid selling drugs to [...]
Report Spotlights Marketing During COVID-19
A new report from Reuters Events offers guidance for pharmaceutical industry solutions providers looking for fresh insights into marketing strategies [...]
ICER Hosting Series on Drug Pricing During a Pandemic
The Institute for Clinical and Economic Review (ICER) is scheduled to host a three-part series focused on drug pricing during [...]
Report: European Drug Regulatory Network Faces Uncertain, Complex Future
A new strategy produced by European regulators considers future challenges for the European drug regulatory network, The Pink Sheet reports. [...]
ICER Outlines Planned Review of High Cholesterol Treatments
The Institute for Clinical and Economic Review (ICER) in a recently-released document outlines its planned review of high cholesterol treatments. [...]
Panel Discusses Provider Prospective on Value-Based Care for mBC
A recent panel discussion on AJMC's Peer Exchange discusses how providers identify value-based care opportunities for metastatic breast cancer. The [...]
Evidation Looks to Bolster Platform to Include Virtual Treatment
After generating $45 million in investments, Evidation is looking to expand its virtual research platform to include digital interventions and [...]
Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent [...]
ICER President: Remdesivir Price was ‘Responsible’ Decisions
The Institute for Clinical and Economic Review's president, Steven Pearson, says Gilead's decision to price its COVID-19 treatment remdesivir at [...]